Monod Bio, a Seattle-based AI-enabled protein design company, and SignalChem Biotech Inc., a wholly-owned subsidiary of Sino Biological, Inc. announced a non-exclusive licensing agreement covering Monod Bio's proprietary LuxSit de novo luciferase technology and NovoBodies.

Under the terms of the agreement, SignalChem Biotech may incorporate the Monod Bio technologies into custom luminescent assay development and protein-fusion services offered to third-party customers for research use. The collaboration expands SignalChem's specialized CRO capabilities and supports Sino Biological's broader strategy of incorporating AI-enabled technologies across its global life science tools and services portfolio.

"This agreement and the corresponding licensed technology strengthen our ability to help customers obtain high-quality discovery candidates more rapidly and address complex biological questions," said Dr. Rob Burgess, Chief Business Officer of Sino Biological.

Monod Bio's LuxSit is an AI-designed luciferase engineered for use in robust luminescent biosensors, while its NovoBodies are compact, highly stable binding proteins engineered for high-performance recognition of various targets.

"SignalChem Biotech and Sino Biological have the scientific expertise, customer reach and service infrastructure to bring these technologies to a broad customer base," said Daniel Silva Manzano, PhD, Chief Executive Officer of Monod Bio. "This partnership expands the reach of our platform and reinforces the value of our Monod Inside model for integrating AI-designed proteins into commercial products and services."